{"entity":{"id":"nct06456138","kind":"trial","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","aka":[],"tldr":"A phase 1/2 trial of trametinib, anlotinib and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.","summary":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC is a phase 1/2, interventional study registered as NCT06456138 by Shanghai Chest Hospital, with a registry enrolment figure of 60 participants, started 2024-07-01 and due to reach its primary completion in 2026-06-30. Interventions recorded: Trametinib; Anlotinib; Tislelizumab. Conditions listed: KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor. Primary outcome: RP2D; PFS. Lung eligibility wording from the registry: \"According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with locally advanced (stage III B/III C), metastatic or recurrent (stage IV) NSCLC confirmed by histology or cytology who are unable to undergo surgery and radical concomitant radiochemotherapy and are confirmed to\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06456138","url":"https://clinicaltrials.gov/study/NCT06456138"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["trametinib","anlotinib","tislelizumab"],"companies":["beone","sino-biopharm","novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06456138","phase":"1/2","setting":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant Advanced Non-small Cell Lung Cancer Patients: a Multi-center, Open-label, Phase 1/2 Study","sponsor":"Shanghai Chest Hospital","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06456138/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}